Pharvaris (NASDAQ:PHVS) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Pharvaris (NASDAQ:PHVS) from a hold rating to a sell rating in a report issued on Saturday.

A number of other brokerages have also weighed in on PHVS. Wolfe Research started coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Citigroup restated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Morgan Stanley lifted their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a report on Thursday, June 25th. Finally, Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and an average price target of $50.08.

Pharvaris Price Performance

Shares of PHVS stock opened at $33.55 on Friday. The firm has a market cap of $2.19 billion, a P/E ratio of -10.55 and a beta of -2.34. Pharvaris has a 1-year low of $19.12 and a 1-year high of $36.60. The firm’s 50-day simple moving average is $32.23 and its 200-day simple moving average is $29.06.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. Analysts expect that Pharvaris will post -3.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the transaction, the insider owned 66,083 shares in the company, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director owned 315,167 shares in the company, valued at $11,185,276.83. The trade was a 8.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 303,356 shares of company stock worth $9,746,065.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. venBio Partners LLC grew its stake in shares of Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. raised its holdings in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after buying an additional 425,000 shares during the period. Commodore Capital LP lifted its position in Pharvaris by 1.6% during the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after acquiring an additional 29,525 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Pharvaris in the 3rd quarter worth approximately $43,282,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.